These results are consistent with our previous work showing around 20-30% of SCLC tumors staining for p-Met, vimentin, Snail1 and SPARC and around 50% of cases considered overexpressed (median as cut-off) for Met and E-cadherin. This evidence concerns the gene SPARC and small cell lung carcinoma.